TEVA-ANASTROZOLE TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

ANASTROZOLE

제공처:

TEVA CANADA LIMITED

ATC 코드:

L02BG03

INN (국제 이름):

ANASTROZOLE

복용량:

1MG

약제 형태:

TABLET

구성:

ANASTROZOLE 1MG

관리 경로:

ORAL

패키지 단위:

30

처방전 유형:

Prescription

치료 영역:

ANTINEOPLASTIC AGENTS

제품 요약:

Active ingredient group (AIG) number: 0128681001; AHFS:

승인 상태:

APPROVED

승인 날짜:

2014-12-01

제품 특성 요약

TEVA-ANASTROZOLE
Page 1 of 68
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TEVA-ANASTROZOLE
Anastrozole Tablets
Tablet, 1 mg, Oral
Teva Standard
Non-Steroidal Aromatase Inhibitor (L02BG03)
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Canada
www.tevacanada.com
Date of Initial Authorization:
October 25, 2012
Date of Revision:
March 16, 2023
Submission Control Number: 271296
TEVA-ANASTROZOLE
Page 2 of 68
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Musculoskeletal
03/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION………………………………………………………………………5
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
....................................................................................................................
4
1.2
Geriatrics
....................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................. 4
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.......................................................... 5
4.4
Administration
............................................................................................................
5
4.5
Missed Dose
..............................................................